Want to see CHRN full AI Analyst Report?
Top Page
ChronoScale
(NASDAQ:CHRN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$19.50
▼(-9.05% Downside)
Action:Reiterated
Date:10/02/26
The score is held down primarily by weak financial performance—large ongoing losses, shrinking equity, and continued negative operating and free cash flow. Technicals are neutral-to-soft with the stock below key short- and mid-term moving averages. Offsetting factors include positive corporate developments (divestiture and expanded AI infrastructure contracts/partnership), but valuation support is limited due to negative earnings and no dividend yield provided.
Positive Factors
Contracted AI Revenue
The expanded customer commitments materially increase ChronoScale’s contracted AI infrastructure pipeline and could improve revenue visibility over the next several quarters. If deployments occur as planned, the larger base may support operating scale and strengthen the company’s position in accelerated computing.
Negative Factors
Persistent Unprofitability
ChronoScale’s gross margin has remained around 53%, but revenue scale is currently insufficient to absorb its very large operating expenses. Persistent losses reduce retained capital and make the business model dependent on substantial growth or a significant improvement in operating efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Contracted AI Revenue
The expanded customer commitments materially increase ChronoScale’s contracted AI infrastructure pipeline and could improve revenue visibility over the next several quarters. If deployments occur as planned, the larger base may support operating scale and strengthen the company’s position in accelerated computing.
Read all positive factors
ChronoScale Key Performance Indicators (KPIs)
ChronoScale (CHRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.82B
Dividend YieldN/A
Average Volume (3M)132.48K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth-34.08%
EPS Growth26.18%
CountryUS
Employees86
SectorTechnology
Sector Strength88
IndustryInformation Technology Services
Share Statistics
EPS (TTM)-5.39
Shares Outstanding145,637,450
10 Day Avg. Volume114,123
30 Day Avg. Volume132,480
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.32
Price to Sales (P/S)1.64
P/FCF Ratio-1.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.00Price Target Upside49.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$178.30M
ChronoScale Business Overview & Revenue Model
Company Description
ChronoScale Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, ...
ChronoScale Earnings Call Summary
Earnings Call Date:Jul 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Negative
The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.Positive Updates
Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.
Negative Updates
Significant Revenue Decline
Second quarter 2025 revenue of $2.1 million was significantly lower compared to $5 million in the second quarter of 2024, due to delays in Enterprise Health sales.
Read all updates
Q2-2025 Updates
Positive
Negative
Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.
Read all positive updates
Company Guidance
During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.ChronoScale Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
14
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
ChronoScale Technical Analysis
Neutral
21.44
Price Trends
20.60
Negative
20.31
Negative
15.06
Positive
Market Momentum
-0.22
Positive
45.48
Neutral
16.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRN, the sentiment is Neutral. The current price of 21.44 is above the 20-day moving average (MA) of 19.77, above the 50-day MA of 20.60, and above the 200-day MA of 15.06, indicating a neutral trend. The MACD of -0.22 indicates Positive momentum. The RSI at 45.48 is Neutral, neither overbought nor oversold. The STOCH value of 16.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CHRN.
ChronoScale Risk Analysis
ChronoScale disclosed 60 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ChronoScale Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
52 Neutral | $37.01M | -3.59 | -92.01% | ― | -1.06% | 82.17% | |
51 Neutral | $37.07M | -7.92 | -149.08% | ― | 3.72% | 43.78% | |
50 Neutral | $8.02M | -0.66 | -88.90% | ― | 72.50% | 58.34% | |
49 Neutral | $2.82B | -2.65 | -177.40% | ― | -34.08% | 26.18% |
* Technology Sector Average
CHRN
ChronoScale
19.21
13.72
249.91%
HBIO
Harvard Bioscience
8.34
3.94
89.55%
MLSS
Milestone Scientific
0.38
-0.07
-15.63%
LUCY
Innovative Eyewear, Inc.
0.89
-1.11
-55.40%
ChronoScale Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsRegulatory Filings and Compliance
ChronoScale expands AI infrastructure contracts, refines growth focus
Positive
Oct 2, 2026
ChronoScale completed the sale of its Ekso Bionics business unit on September 30, 2026, and subsequently terminated Ekso’s Chief Operating Officer, Jason C. Jones, on the same date, with Ekso entering into a severance and release agreement g...
Business Operations and StrategyPrivate Placements and Financing
ChronoScale amends term loan, extends debt maturity
Positive
Sep 16, 2026
On September 12, 2026, ChronoScale Intermediate, LLC and Ekso Bionics, Inc. amended their existing $2.0 million secured term loan agreement with B. Riley Commercial Capital, LLC, under which the full principal amount remained outstanding at the ti...
Business Operations and StrategyRegulatory Filings and Compliance
ChronoScale, Microsoft expand AI infrastructure partnership deployment
Positive
Aug 27, 2026
On August 27, 2026, ChronoScale announced a strategic partnership with Microsoft to develop a 50-megawatt AI compute deployment in North America, integrating NVIDIA GB300 NVL72 systems and advanced liquid-cooling infrastructure. The project is des...
Business Operations and StrategyExecutive/Board Changes
ChronoScale confirms CFO role with new compensation package
Positive
Aug 18, 2026
On August 16, 2026, ChronoScale Corporation entered into an Offer of Continued Employment and a Covenants Agreement with Chief Financial Officer Jerome Wong, confirming his role and setting his annual base salary at $400,000 with a target performa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.